Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification

  • I. Yonezawa Shizuoka Saiseikai General Hospital
  • M. Waki Hamamatsu University School of Medicine
  • Y. Tamura Shizuoka Saiseikai General Hospital
  • R. Onoda Shizuoka Saiseikai General Hospital
  • M. Narushima Shizuoka Saiseikai General Hospital
  • T. Ishizuka Shizuoka Saiseikai General Hospital
  • S. Tajima Shizuoka Saiseikai General Hospital
Keywords: angiosarcoma, mucinous cystadenoma, surgical resection, chemotherapy, gemcitabine, MYC


Angiosarcoma is a rare and aggressive type of sarcoma, and primary angiosarcoma of the ovary is extremely rare. We report the case of a 29-year-old woman who was diagnosed with ovarian angiosarcoma and possible bone metastases. We treated this patient with a gemcitabine-based regimen as postoperative adjuvant chemotherapy, after which she achieved at least 7 years of progression-free survival, an extremely long duration given the aggressive features of this tumour. We retrospectively performed immunohistochemical analyses and fluorescence in situ hybridization to make a pathology diagnosis and to investigate the tumour features. MYC amplification and c-Myc protein overexpression were positively detected. It might be possible to correlate the effectiveness of the gemcitabine-based chemotherapeutic regimen with MYC gene amplification and c-Myc protein overexpression.
How to Cite
Yonezawa, I., Waki, M., Tamura, Y., Onoda, R., Narushima, M., Ishizuka, T., & Tajima, S. (2014). Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification. Current Oncology, 21(6), e782-e789.
Case Report